Get started
CYCLOPHARM LTD.CYCLOPHARM LTD.CYCLOPHARM LTD.

CYCLOPHARM LTD.

No trades
OverviewFinancialsNewsCommunityETFs

Chart


Full chart

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪77.80 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.079436 USD
Net income (FY)
‪−8.16 M‬ USD
Revenue (FY)
‪17.06 M‬ USD
Shares float
‪61.92 M‬
Beta (1Y)
0.55

Employees


Employees (FY)
95
Change (1Y)
+8 +9.20%
Revenue / Employee (1Y)
‪179.56 K‬ USD
Net income / Employee (1Y)
‪−85.95 K‬ USD

About Cyclopharm Limited


Sector
Health Technology
Industry
Medical Specialties
CEO
James M. McBrayer
Website
cyclopharm.com
Headquarters
Kingsgrove
Founded
2005
IPO date
Jan 18, 2007
Identifiers
2
ISIN AU000000CYC5
Cyclopharm Ltd. is a radiopharmaceutical company, which engages in diagnostic imaging in lung health. It manufactures and sells medical devices and pharmaceutical products. It operates through Technegas and Molecular Imaging segments. The Technegas segment supplies diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders and cardiac disease. The company was founded in 1984 and is headquartered in Kingsgrove, Australia.

Check out other big names from the same industry as CYCMF.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

ETFs holding the stock


DACE
Dimensional Australian Core Equity Trust Units
Weight
0.00%
Market value
‪20.92 K‬
USD

Explore more ETFs 

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange CYCLOPHARM LTD. stocks are traded under the ticker CYCMF.
Yes, you can track CYCLOPHARM LTD. financials in yearly and quarterly reports right on TradingView.
CYCLOPHARM LTD. is going to release the next earnings report on Feb 25, 2026. Keep track of upcoming events with our Earnings Calendar.
CYCLOPHARM LTD. revenue for the last half-year amounts to ‪10.14 M‬ USD, despite the estimated figure of ‪10.39 M‬ USD. In the next half-year revenue is expected to reach ‪12.21 M‬ USD.
CYCMF net income for the last half-year is ‪−5.06 M‬ USD, while the previous report showed ‪−3.52 M‬ USD of net income which accounts for −43.67% change. Track more CYCLOPHARM LTD. financial stats to get the full picture.
As of Feb 14, 2026, the company has 95 employees. See our rating of the largest employees — is CYCLOPHARM LTD. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CYCLOPHARM LTD. EBITDA is ‪−8.83 M‬ USD, and current EBITDA margin is −47.32%. See more stats in CYCLOPHARM LTD. financial statements.
Like other stocks, CYCMF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CYCLOPHARM LTD. stock right from TradingView charts — choose your broker and connect to your account.